|
|Section2= |Section3= }} Fexinidazole is an antiparasitic agent. It has activity against ''Trypanosoma cruzi'', ''Tritrichomonas foetus'', ''Trichomonas vaginalis'', ''Entamoeba histolytica'',〔 ''Trypanosoma brucei,'' and ''Leishmania donovani''. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone 〔 Fexinidazole was discovered by the German pharmaceutical company Hoechst AG, but its development as a pharmaceutical was halted in the 1980s.〔(【引用サイトリンク】 Jump-Start on Slow Trek to Treatment for a Disease )〕 Fexinidazole is now being studied through a collaboration between Sanofi and the Drugs for Neglected Diseases Initiative for the treatment of Chagas disease and human African trypanosomiasis (sleeping sickness).〔(【引用サイトリンク】 url = http://www.dndi.org/newsletters/n17/en/10_1.htm )〕〔(【引用サイトリンク】 publisher = DNDi )〕 Fexinidazole is the first drug candidate for the treatment of advanced-stage sleeping sickness in thirty years. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Fexinidazole」の詳細全文を読む スポンサード リンク
|